On the fly News and insights, exclusive to thefly.com

LLY

Eli Lilly

$217.08 /

-4.51 (-2.04%)

, BIIB

Biogen

$371.82 /

-2.77 (-0.74%)

07:22
06/24/21
06/24
07:22
06/24/21
07:22

Eli Lilly jumps on expedited plans for Alzheimer's drug, Biogen falls

Eli Lilly (LLY) announced that the Food and Drug Administration granted Breakthrough Therapy designation for donanemab, its investigational antibody therapy for Alzheimer's disease. Lilly intends to submit a biologics license application for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. The safety, tolerability and efficacy of donanemab are also being evaluated in the ongoing Phase 3 study TRAILBLAZER-ALZ 2, the company said in a statement. The Phase 2 trial, TRAILBLAZER-ALZ, studied the efficacy and safety of donanemab in patients with early, symptomatic Alzheimer's. Shares of Eli Lilly are up 9%, or $18.50, to $235.60 following the news. Shares of Biogen (BIIB), who recently received FDA approval for its Alzheimer's treatment, are down 6% to $350.02 in premarket trading.

LLY

Eli Lilly

$217.08 /

-4.51 (-2.04%)

BIIB

Biogen

$371.82 /

-2.77 (-0.74%)

  • 24

    Jun

  • 25

    Jun

LLY Eli Lilly
$217.08 /

-4.51 (-2.04%)

06/15/21 JPMorgan
Eli Lilly price target raised to $260 from $240 at JPMorgan
06/14/21 Goldman Sachs
Eli Lilly price target raised to $270 from $252 at Goldman Sachs
06/08/21 Baird
Baird upgrades Biogen to Neutral after 'fatal blow' to bear thesis
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
BIIB Biogen
$371.82 /

-2.77 (-0.74%)

06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Jefferies
Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback
06/18/21 BofA
BofA upgrades Prothena to Neutral on PRX012 potential following Aduhelm approval
06/18/21 Piper Sandler
Biogen upgraded to Overweight from Neutral at Piper Sandler

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.